Last Updated: 05/17/12
Next-Generation DNA Sequencing as a Tool for Clinical Decision-Making in Cancer Patient Management
Hyatt Regency Bethesda
7400 Wisconsin Avenue
Bethesda, MD 20814
May 3 – 4, 2012
Agenda
Thursday, May 3, 2012
| Session Time | Topic Time | Title | Presenter |
|---|---|---|---|
| 7:30-8:00 a.m. | Registration | ||
| 8:00-8:15 | Welcome and Opening Remarks Goals of the Meeting and Charge for the Breakout Sessions |
Barbara Conley, M.D. and Mickey Williams, Ph.D. |
|
| 8:15-8:45 | Keynote Address Translating NGS Data Into a Clinically Actionable Assay |
Elaine Mardis, Ph.D. | |
| 8:45-10:45 | Assay Development and Performance Session Chairs: Richard Press and Mark Raffeld |
||
| 8:45 | NGS in the Clinic — Considerations for Molecular Pathologists | Jane Gibson, Ph.D. | |
| 9:05 | Clinical-Grade Next Generation Sequencing: Assay Design & Validation | Richard Press, M.D., Ph.D. | |
| 9:25 | Lessons Learned From Sequencing Clinical Specimens | Maureen Cronin, Ph.D. | |
| 9:45-9:55 | BREAK | ||
| 9:55 | Utility of Multi-analyte Assays for Mutation Detection | John Iafrate, M.D., Ph.D. | |
| 10:15 | Establishing Clinical-grade Assays for Support of Drug Trials | Patrick Hurban, Ph.D. | |
| 10:35 | Panel Discussion | ||
| 10:50-11:45 | Bioinformatics and Analysis Session Chairs: John Quackenbush and Jack Collins |
||
| 10:50 | The Road to Personalized Medicine is Paved With Data and Information | John Quackenbush, Ph.D. | |
| 11:10 | Comprehensive Detection of Variation in Thousands of Whole Genome Sequences | Stephen Lincoln | |
| 11:30 | Panel Discussion | ||
| 11:45-1:30 | LUNCH | ||
| 1:30-3:50 | Clinical, Regulatory, and Ethical issues Session Chairs: William Pao and Barbara Conley |
||
| 1:35 | Challenges in Incorporating Integral NGS Into Early Clinical Trials | Shivaani Kummar, M.D. | |
| 1:55 | So Now What Do We Do? Deciding on Use of NGS in the Clinical Laboratory | Stanley Hamilton, M.D. | |
| 2:15 | CLIA Hurdles for NGS — CAP Perspective | Sashikant Kulkarni, M.S., Ph.D. | |
| 2:35 | Regulatory Considerations for Investigational Assays — Planning for Success | Elizabeth Mansfield, Ph.D. | |
| 2:55 | Direct to Consumer Sale | Pamela McAllister, Ph.D. | |
| 3:05 | Can I Really Give INFORMED Consent If I Don't Know What It Means? NGS From the Patient Perspective | Elda Railey | |
| 3:15 | Panel Discussion | ||
| 3:30-3:50 | BREAK | ||
| 4:00-6:00 | Breakout Groups Each group will highlight key issues and brainstorm solutions. |
||
| Waterford: Assay Development and Performance — 1A | Richard Press, M.D., Ph.D. and Paul Meltzer, M.D., Ph.D. |
||
| Embassy/Potomac/Patuxent: Assay Development and Performance — 1B | Mark Raffeld, M.D. and Mickey Williams, Ph.D. |
||
| Diplomat/Ambassador: Data Analysis — 2 | John Quackenbush, Ph.D. and Jack Collins, Ph.D. |
||
| Old Georgetown: Clinical, Regulatory, and Ethical Issues — 3 | William Pao, M.D., Ph.D. and Barbara Conley, M.D. |
Friday, May 4, 2012
| Session Time | Topic Time | Title | Presenter |
|---|---|---|---|
| 8:00-8:45 a.m. | Keynote Address Tumor-Genome-Directed Anti-Cancer Therapy: Using Lung Cancer and Melanoma as a Paradigm |
William Pao, M.D., Ph.D. | |
| 8:45-11:45 | Presentations by Breakout Groups 25 minutes plus 15 minutes floor discussion for each |
||
| 8:45 | Assay Development and Performance — 1A | Richard Press, M.D., Ph.D. | |
| 9:25 | Assay Development and Performance — 1B | Mark Raffeld, M.D. | |
| 10:05-10:25 | BREAK | ||
| 10:25 | Data Analysis | John Quackenbush, Ph.D. | |
| 11:05 | Clinical, Regulatory, and Ethical issues | William Pao, M.D., Ph.D. | |
| 11:45-Noon | General Floor Discussion and Wrap-Up | Barbara Conley, M.D. and Mickey Williams, Ph.D. | |
| Noon | ADJOURN |
We thank the Association for Molecular Pathology for their assistance in planning this program.
